Carillon Eagle Mid Cap Growth Fund’s Views on Dexcom (DXCM)

Carillon Tower Advisers, an investment management company, released its “Carillon Eagle Mid Cap Growth Fund” third-quarter 2025 investor letter. A copy of the letter can be downloaded here. In the third quarter, the equity markets continued their rally, fueled by enthusiasm for AI, limited evidence of inflationary effects from tariffs, and expectations for further interest rate cuts from the U.S. Federal Reserve. Mid-cap stocks also maintained their positive gains during the quarter. The Russell Midcap Growth Index (up 2.78%) underperformed the Russell Midcap® Value Index (up 6.16%) in the quarter. The letter further shared the firm’s detailed views on Cyclicals, Healthcare, Information Technology, Financials, and Consumer sectors. In addition, you can check the fund’s top 5 holdings to determine its best picks for 2025.

In its third-quarter 2025 investor letter, Carillon Eagle Mid Cap Growth Fund highlighted stocks such as DexCom, Inc. (NASDAQ:DXCM). DexCom, Inc. (NASDAQ:DXCM) is a medical device company that develops and commercializes continuous glucose monitoring (CGM) systems. The one-month return of DexCom, Inc. (NASDAQ:DXCM) was -10.14%, and its shares lost 20.18% of their value over the last 52 weeks. On November 24, 2025, DexCom, Inc. (NASDAQ:DXCM) stock closed at $62.21 per share, with a market capitalization of $24.396 billion.

Carillon Eagle Mid Cap Growth Fund stated the following regarding DexCom, Inc. (NASDAQ:DXCM) in its third quarter 2025 investor letter:

“DexCom, Inc. (NASDAQ:DXCM) is a medical device company that helped pioneer the design and development of continuous glucose monitoring systems (CGMs). The company has been under pressure since posting unexpectedly bad results in the second quarter of 2024, despite improving or at least stabilizing revenues and operating profits since then. Recently, there have been concerns over accuracy issues with Dexcom’s latest generation G7 continuous glucose monitor. The company is addressing the issue, but so far it’s unclear whether these issues have impaired the brand and caused a loss of market share.”

Why DexCom Inc. (DXCM) Soared Last Week

DexCom, Inc. (NASDAQ:DXCM) is not on our list of 30 Most Popular Stocks Among Hedge Funds. According to our database, 60 hedge fund portfolios held DexCom, Inc. (NASDAQ:DXCM) at the end of the second quarter, the same as in the previous quarter. For the third quarter of 2025, DexCom, Inc. (NASDAQ:DXCM) reported global revenue of $1.21 billion, compared to $994 million in the third quarter of 2024. While we acknowledge the risk and potential of DexCom, Inc. (NASDAQ:DXCM) as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than DexCom, Inc. (NASDAQ:DXCM) and that has 10,000% upside potential, check out our report about this cheapest AI stock.

In another article, we covered DexCom, Inc. (NASDAQ:DXCM) and shared the list of best QQQ stocks to buy according to Wall Street analysts. In Q3 2025, Aristotle Atlantic Core Equity Strategy initiated a position in DexCom, Inc. (NASDAQ:DXCM). In addition, please check out our hedge fund investor letters Q3 2025 page for more investor letters from hedge funds and other leading investors.

READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.

Disclosure: None. This article is originally published at Insider Monkey.